Screening hits and secondary confirmation concentration response assays.

<p><b>A–E</b>, concentration-response curves generated from the data obtained in the screen (top panels) compared to those curves generated from cherry-picked wells containing ixabepilone (A), paclitaxel (B), gefitinib (C) or dasatinib (D) or lapatinib (E). For all curves, the cells were plated as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0108283#pone-0108283-g003" target="_blank">Fig. 3A</a> and treated as described in 3B. <b>F</b>, Concentration-response curve generated by treating 2D BT-474+HF+HE (“2T”), 3D BT-474+HF+HE (“3T”), 2D HF+HE (“2N”), or 3D HF+HE (“3N”) co-cultures with concentrations of lapatinib ranging over 5 logs for 48 hours. Cell viability was assessed using the CellTiterGLO assay, as described for the screens, and normalized to vehicle control. Experiment was performed in triplicate, <i>bars</i>, standard deviation.